MYNZ MAINZ BIOMED BV

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 

BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, joins advocacy organizations around the world in recognizing Colorectal Cancer Awareness Month in March. Colorectal cancer is the third most common cancer globally, with more than 1.9 million new cases in 2020. This year, Mainz Biomed will be hosting several educational and training events throughout Germany to raise awareness of the importance of early detection.

“We have developed these events to support the colorectal cancer community, as this disease is the third most common cancer globally and the fourth leading cause of cancer death in the US,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our goal is to reduce these statistics and save lives by raising awareness about the simplicity and efficacy of using at-home CRC detection kits, like ColoAlert. Our non-invasive DNA stool test allows people to screen themselves in the comfort of their own home and then receive a follow-up notification from their physician to discuss results and next steps.”

Upcoming Colorectal Cancer Awareness Month Events

Professionals

Training Sessions for gastroenterologists, healthcare providers

Gastro-Update Conference;

#1 Friday and Saturday, March 10-11, 2023 (Time TBD)

Rheingoldhalle; Mainz

#2 Friday and Saturday, March 24-25, 2023 (Time TBD)

Berlin Congress Center; Berlin/

Public

Educational Event for patients, families, caregivers, advocates

Saturday, March 11, 2023 (09:00-16:00)

(Outdoor event venue TBD); Mainz Altstadt

Mainz Biomed invites others to further amplify awareness of CRC by using the #BlueForCRC and #CRCAwareness hashtags on social media and “going blue” on Friday, March 3 by dressing in blue!

For media inquiries, please contact In Europe:

MC Services AG

Anne Hennecke/Caroline Bergmann

20





In the US:

Spectrum Science

Melissa Laverty/Valerie Enes



For investor inquiries, please contact 



EN
01/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MAINZ BIOMED BV

 PRESS RELEASE

Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive ...

Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples Mainz Biomed to Present Industry Leading Results: 100% Sensitivity and 95% Specificity BERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in Chicago, Illinois. At the conference the Company will present its poster titled “BLOOD-BASE...

 PRESS RELEASE

Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic...

Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update Company to Focus on Pancreatic Cancer Detection Business in the U.S., Strategic Asset Sales and Future Strategic Transaction BERKELEY, Calif. and MAINZ, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its liquidity position, transition the business to a focus on its pancreatic cancer detection program in the U.S., and provide fle...

 PRESS RELEASE

Mainz Biomed to Present Results of Pancreatic Cancer Verification Stud...

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San Diego BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meetin...

 PRESS RELEASE

Mainz Biomed Provides Review of 2025 Highlights

Mainz Biomed Provides Review of 2025 Highlights Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectStudy Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...

 PRESS RELEASE

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another important milestone in Mainz Biomed’s European growth strategy and highlights the increasing importance of innovati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch